Trader consensus on Polymarket reflects a 92.5% implied probability against a new coronavirus pandemic in 2026, driven by sustained low global SARS-CoV-2 activity per WHO and CDC surveillance data. As of late March 2026, test positivity hovered at 2.3%, with infections declining or stable in most U.S. states and only 37 countries reporting new COVID-19 deaths over a recent 28-day period. The emerging BA.3.2 variant, dubbed "Cicada" for its mutations enabling immune escape, has spread to over 20 countries but accounts for under 0.2% of U.S. sequences amid effective vaccination and prior immunity. This stability echoes COVID-19's transition to endemicity, bolstered by genomic monitoring. Realistic challenges include rapid BA.3.2 dominance causing hospitalization surges or a novel zoonotic spillover prompting WHO public health emergency declaration, with key vaccine composition data due in May.